The first participant has been enrolled in the Phase 1/2 clinical trial CEDAR evaluating Graphite Bio’s investigational gene editing therapy…
Articles by Marisa Wexler, MS
The U.S. Food and Drug Administration (FDA) has cleared Beam Therapeutics to start clinical testing of BEAM-101, the company’s…
In support of its work to develop a rapid test that can be used to diagnose sickle cell disease…
A point-of-care, low-cost device called Gazelle — that’s both portable and easy to use — can accurately diagnose…
Emmaus Life Sciences is seeking the approval of Endari (L-glutamine), an oral treatment for sickle cell disease…
GPH101, Graphite Bio’s investigational gene editing therapy, is able to correct the disease-causing mutation in blood stem cells of…
The National Institutes of Health (NIH) has awarded a $10.5-million grant to support several research projects seeking to improve care…
The Sickle Cell Consortium, a U.S.-based nonprofit, is hosting a virtual event in late August that will focus on…
Endari (L-glutamine), an approved oral treatment for sickle cell disease (SCD), has now been added to the Preferred…
Emmaus Life Sciences has submitted an application seeking the approval of its oral medication Endari (L-glutamine) to treat…